Can I Take Omega-3 (EPA/DHA) With Spironolactone?

The short answer: omega-3 and spironolactone can be taken together, with one caveat

For the vast majority of women, taking an omega-3 supplement alongside spironolactone is safe. No published human pharmacokinetic study shows that EPA or DHA changes how your body absorbs, metabolizes, or excretes spironolactone. The concern that does exist is pharmacodynamic, meaning both substances influence platelet behavior through separate biological pathways, and at high enough doses those effects can add up.

Understanding the distinction between these two types of interaction matters. A pharmacokinetic interaction changes drug levels in your blood. A pharmacodynamic interaction changes what a drug does even if blood levels stay the same. The omega-3 plus spironolactone pairing is the second type, and it only becomes clinically significant at higher omega-3 doses or in women who already have bleeding risk factors.

How spironolactone works in women

Spironolactone is an aldosterone antagonist and androgen receptor blocker. Endocrinologists and dermatologists prescribe it off-label for PCOS-related hirsutism and hormonal acne far more often than for its on-label indication of fluid retention, because it directly competes with testosterone and dihydrotestosterone (DHT) at the receptor level.

Spironolactone for PCOS and hyperandrogenism

PCOS affects 6-13% of women of reproductive age worldwide, making it the most common endocrine disorder in women. Elevated androgens drive acne, hirsutism, and female pattern hair loss in many of these women. Spironolactone at doses of 50-200 mg/day reduces these androgenic effects. A 2023 randomized controlled trial published in the New England Journal of Medicine confirmed that spironolactone significantly reduced acne lesion counts compared with placebo in adult women, with 50 mg and 100 mg doses both performing meaningfully better than placebo over 24 weeks.

How spironolactone affects your hormones across the menstrual cycle

Because spironolactone raises progesterone and can alter estrogen metabolism, menstrual irregularity is common in premenopausal women, particularly during the first three cycles. Your prescriber may pair it with a combined oral contraceptive for cycle regulation and, critically, for contraception (more on that below). Dose escalation is usually done in 25-50 mg increments to limit the dizziness that comes from its diuretic effect.

Potassium and electrolyte monitoring

Spironolactone blocks aldosterone, which increases potassium retention. Women with normal kidney function taking standard PCOS doses (<100 mg/day) rarely develop clinically significant hyperkalemia, but your clinician will typically check a basic metabolic panel at baseline and then periodically. If you eat a very high-potassium diet or take potassium supplements, tell your provider.

How omega-3 EPA/DHA works and why women take it

Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are long-chain polyunsaturated fats found in fatty fish and concentrated fish-oil capsules. They are among the most widely taken supplements in the United States. The 2017-2018 NHANES data showed that approximately 19% of U.S. Adults reported taking a fish oil supplement in the past 30 days, with women reporting use more often than men.

What EPA and DHA actually do

EPA and DHA are incorporated into cell membranes, where they compete with arachidonic acid in the production of eicosanoids. This shifts the balance from pro-inflammatory prostaglandins and thromboxanes toward anti-inflammatory resolvins and protectins. One downstream consequence: thromboxane A2, the platelet-activating compound, is produced in smaller amounts. This mildly reduces platelet aggregation, an effect that is measurable at doses above 3 g combined EPA+DHA per day.

Omega-3 and triglycerides

The clearest clinical application of high-dose omega-3 is triglyceride reduction. The FDA has approved prescription-strength icosapentaenoic acid (Vascepa, 4 g/day) and EPA+DHA (Lovaza, 4 g/day) for severe hypertriglyceridemia. At over-the-counter doses of 1-2 g/day, the triglyceride-lowering effect is modest but measurable. This matters in the spironolactone context because women with PCOS frequently have elevated triglycerides as part of their metabolic profile, and omega-3 co-therapy may meaningfully support that component of cardiometabolic risk.

Why PCOS women specifically may benefit from omega-3

A 2018 meta-analysis in Reproductive Biology and Endocrinology covering 6 randomized controlled trials found that omega-3 supplementation in women with PCOS significantly reduced triglycerides, fasting insulin, and testosterone compared with placebo. The testosterone reduction was modest, but it is directionally aligned with spironolactone's androgenic blockade. This makes omega-3 one of the more evidence-supported supplements in the PCOS supplement space.

The actual interaction: what the evidence says

There is no documented pharmacokinetic drug interaction between spironolactone and omega-3 fatty acids in any published human study or in the Natural Medicines database. Spironolactone is metabolized primarily via CYP1A2 and non-CYP sulfotransferase pathways. EPA and DHA do not meaningfully inhibit or induce these enzymes at dietary or supplement doses.

The antiplatelet overlap

Both spironolactone and omega-3 have mild antiplatelet properties through distinct mechanisms.

Spironolactone's antiplatelet effect is mediated partly through mineralocorticoid receptor blockade on platelet surfaces. A 2020 study in the Journal of the American Heart Association noted that mineralocorticoid receptor antagonists modestly reduce platelet aggregation, though the effect is small at standard clinical doses.

Omega-3 reduces platelet aggregation by reducing thromboxane A2 synthesis. At doses of 1-2 g combined EPA+DHA per day (a typical supplement capsule), this effect is below the threshold that clinical guidelines flag as a surgical bleeding risk. The American Society of Regional Anesthesia (ASRA) and most procedural guidelines use a threshold of greater than 3 g/day as the point where peri-procedural discontinuation of omega-3 becomes advisable.

When should you pay attention to this combination?

The antiplatelet stacking only becomes a practical concern in specific situations:

• You take more than 3 g combined EPA+DHA per day from supplements
• You are also taking aspirin, NSAIDs, or anticoagulants
• You have a clotting disorder or a scheduled surgical or dental procedure
• You bruise very easily or have a history of heavy menstrual bleeding

For the typical woman taking 100 mg spironolactone for PCOS and one standard fish-oil capsule (around 1 g EPA+DHA), the additive antiplatelet effect is not clinically meaningful. No case reports of significant bleeding from this combination appear in the published literature as of early 2025.

The WomanRx framework for evaluating supplement-drug combinations in women distinguishes three tiers of interaction concern. Tier 1 is pharmacokinetic (drug levels change): avoid or separate doses. Tier 2 is pharmacodynamic with a measurable threshold (such as bleeding risk above 3 g/day omega-3): dose-limit the supplement and flag before procedures. Tier 3 is theoretical or subthreshold: monitor for symptoms, no dose change needed. The omega-3 and spironolactone combination sits at Tier 2 only if you exceed 3 g/day of EPA+DHA. At standard supplement doses, it is Tier 3.

Does omega-3 affect spironolactone's hormonal effects?

No published data suggest that omega-3 supplementation changes spironolactone's antiandrogenic potency or its aldosterone-blocking activity. The modest testosterone-lowering effect seen in the Reproductive Biology and Endocrinology meta-analysis is an additive benefit, not an interference. Your acne, hirsutism response, or blood pressure control on spironolactone should not be affected by omega-3 supplementation at standard doses.

Pregnancy, lactation, and contraception: a required conversation

Spironolactone is contraindicated in pregnancy. This is not a gray area. Animal studies have shown that spironolactone and its metabolite canrenone feminize male fetuses through androgen receptor blockade during organogenesis. The FDA labels spironolactone as Pregnancy Category C (first trimester) and with known teratogenic risk in androgen-sensitive fetal development. The practical consensus among reproductive endocrinologists and the position reflected in ACOG clinical guidance is that spironolactone should be discontinued before any attempt to conceive.

Contraception is not optional on spironolactone

Because the risk to a male fetus is real and because spironolactone itself can cause irregular bleeding that obscures missed periods, ACOG recommends that all premenopausal women of reproductive potential taking spironolactone use reliable contraception. A combined oral contraceptive pill is often the preferred choice because it simultaneously regulates cycles and provides contraceptive protection. If you are using progestin-only methods or non-hormonal methods, discuss adequacy of protection with your prescriber.

Trying to conceive

If you want to get pregnant in the next 6-12 months, have a clear discontinuation plan. Most clinicians recommend stopping spironolactone at least one full menstrual cycle before attempting conception, though some prefer a two-to-three cycle washout given its half-life and the uncertainty around fetal exposure timing.

Omega-3 in pregnancy and lactation

Omega-3, by contrast, is not only safe but actively encouraged in pregnancy. DHA is critical for fetal brain and retinal development. ACOG recommends at least 200 mg DHA daily during pregnancy, and many prenatal vitamins include this dose. Omega-3 is also compatible with breastfeeding; DHA transfers into breast milk and supports infant neurodevelopment. There is no concern about giving omega-3 to a breastfeeding woman.

Postpartum and lactation: what to do about spironolactone

Spironolactone is secreted into breast milk. The concentration is low, but no adequate safety data exist in breastfed infants. The Drugs and Lactation Database (LactMed) considers spironolactone generally not recommended during breastfeeding because of insufficient infant safety data and its antiandrogenic hormonal activity. If postpartum acne or PCOS symptoms return, discuss the timing of spironolactone restart with your clinician relative to your weaning plan.

Life stage guide: who benefits most from this combination

Reproductive years with PCOS

This is the highest-value scenario. You are dealing with androgen excess, possibly elevated triglycerides, insulin resistance, and skin or hair changes. Spironolactone addresses the androgen-receptor side. Omega-3 addresses the triglyceride and mild inflammatory side. The combination is not just safe; it is complementary. Use a standard fish oil dose of 1-2 g combined EPA+DHA and keep the dose below 3 g/day unless your clinician specifically prescribes higher for hypertriglyceridemia.

Perimenopause

Perimenopausal women sometimes take low-dose spironolactone (25-50 mg/day) for late-onset hormonal acne or blood pressure support. Omega-3 is commonly used in this life stage for cardiovascular protection and mood. At perimenopausal doses of spironolactone, the antiplatelet concern is even less relevant. The combination is appropriate.

Post-menopause

Spironolactone is used less often for androgenic indications after menopause because androgen levels fall naturally. When it is used post-menopause, usually for blood pressure or heart failure, omega-3 co-therapy for cardiovascular benefit is clinically sensible. The interaction profile does not change with menopause itself.

Hormonal acne without a PCOS diagnosis

Young women in their 20s and 30s taking spironolactone specifically for hormonal acne (dermatologist-prescribed) are among the most common users. Omega-3 may independently reduce inflammatory acne lesions. A 2012 randomized study published in Lipids in Health and Disease found that omega-3 supplementation significantly reduced inflammatory and non-inflammatory acne lesions compared with control, making it a reasonable add-on at 1-2 g/day.

Who this combination is right for, and who should be cautious

Good candidates for both

• Women with PCOS managing androgen symptoms, elevated triglycerides, or insulin resistance
• Women taking spironolactone for hormonal acne who want a supplement-based anti-inflammatory add-on
• Perimenopausal women using low-dose spironolactone for acne or blood pressure
• Any woman taking standard supplement doses of omega-3 (1-2 g EPA+DHA/day)

Women who should flag this to their clinician before adding omega-3

• Anyone taking more than 3 g/day of omega-3 from any source (supplements plus dietary fish concentrate)
• Women who also take aspirin, blood thinners (warfarin, apixaban), or other antiplatelet agents
• Anyone with a planned surgery or dental extraction within two weeks (consider pausing omega-3 7-10 days before, per standard pre-procedure guidance)
• Women with inherited bleeding disorders such as von Willebrand disease

Who should not take spironolactone at all

• Pregnant women or those actively trying to conceive
• Women with severe kidney disease (creatinine >2.5 mg/dL) due to hyperkalemia risk
• Women with Addison's disease or severe adrenal insufficiency
• Anyone with a known hypersensitivity to spironolactone

Practical dosing and monitoring guidance

Omega-3 dose to use alongside spironolactone

Aim for 1-2 g combined EPA+DHA per day from a high-quality fish oil or algal oil supplement. Look for third-party tested products certified by NSF International, USP, or IFOS (International Fish Oil Standards). Algal oil is a good option if you are vegetarian or concerned about marine contaminants; it provides DHA with meaningful EPA content in newer formulations.

Take omega-3 with your largest meal of the day. This improves absorption and reduces the fishy aftertaste that causes many women to stop taking it. Separating the timing from spironolactone is not required based on any pharmacokinetic data, but taking medications with dedicated water separate from oily supplements is a reasonable personal preference.

Monitoring on spironolactone

Your prescriber will order:

• Basic metabolic panel (potassium, creatinine) at baseline, then at 2-4 weeks after any dose change, then every 6-12 months
• Blood pressure checks, especially in the first few weeks
• Menstrual cycle tracking for the first 2-3 cycles

Omega-3 does not alter potassium or renal function and does not interfere with these labs.

Signs that warrant a call to your clinician

• Unusual bruising or prolonged bleeding from minor cuts
• Heavy menstrual bleeding that is new or significantly worse
• Dizziness, near-fainting, or extreme fatigue (could reflect excessive blood pressure lowering)
• Muscle weakness or palpitations (possible hyperkalemia at higher spironolactone doses)

None of these are specific to the omega-3 and spironolactone combination, but they are worth reporting promptly.

The evidence gap: what we do not yet know

Women have been historically underrepresented in cardiovascular and pharmacology trials. Most of what we know about omega-3's antiplatelet effects comes from studies conducted predominantly in men or in mixed-sex cohorts where sex-disaggregated data were not reported. A 2020 analysis in Circulation noted that fewer than 30% of participants in major omega-3 cardiovascular trials were women, and subgroup analyses by sex were inconsistent across trials.

Similarly, spironolactone's antiplatelet mechanism has not been characterized specifically in premenopausal women. Platelet function varies across the menstrual cycle: estrogen generally enhances platelet aggregation and progesterone modulates it, meaning the net antiplatelet effect of omega-3 or spironolactone may differ depending on where a woman is in her cycle. This is an area where the research genuinely has not caught up with clinical need, and extrapolation from male or mixed-sex data is the current standard of practice.

As the WomanRx editorial board member reviewing this article, Dr. Priya Sharma notes: "In my clinical practice, I have not seen meaningful bleeding concerns from women combining standard fish oil doses with spironolactone for PCOS. The interaction is real at high doses but theoretical at the doses most of my patients are actually using. The more clinically pressing conversation is always contraception, because the teratogenic risk of spironolactone in pregnancy is concrete and the consequences are serious."